Vontobel Holding’s Aurinia Pharmaceuticals AUPH Stock Holding History

Vontobel Holding’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-80,000	Closed	-$457K	–	1084
2024 Q2	$457K	Hold	80,000	–	–	﹤0.01%	797
2024 Q1	$401K	Sell	80,000 -2,000	-2%	-$13.6K	﹤0.01%	833
2023 Q4	$737K	Hold	82,000	–	–	0.01%	682
2023 Q3	$637K	Hold	82,000	–	–	0.01%	696
2023 Q2	$794K	Buy	82,000 +10,400	+15%	+$108K	0.01%	658
2023 Q1	$785K	Buy	71,600 +15,000	+27%	+$132K	0.01%	650
2022 Q4	$245K	Buy	56,600 +26,000	+85%	+$151K	﹤0.01%	941
2022 Q3	$230K	Hold	30,600	–	–	﹤0.01%	914
2022 Q2	$308K	Buy	30,600 +4,600	+18%	+$51.4K	﹤0.01%	837
2022 Q1	$322K	Buy	26,000 +10,700	+70%	+$165K	﹤0.01%	899
2021 Q4	$350K	Sell	15,300 -17,737	-54%	-$420K	﹤0.01%	892
2021 Q3	$731K	Hold	33,037	–	–	0.01%	685
2021 Q2	$428K	Hold	33,037	–	–	﹤0.01%	808
2021 Q1	$429K	Sell	33,037 -6,293	-16%	-$91.3K	﹤0.01%	707
2020 Q4	$544K	Buy	+39,330	New	+$572K	﹤0.01%	634

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vontobel Holding's AUPH Position: Q3 2024 in Review

Vontobel Holding sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2024, closing a stake of 80,000 shares — an estimated $457K sold.

Vontobel Holding first reported a position in AUPH in Q4 2020 and held it in 15 quarters. The position peaked at $794K in Q2 2023. 183 funds tracked by Wall St. Rank hold AUPH as of Q3 2024.

Vontobel Holding reported no remaining Aurinia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Vontobel Holding sold 80,000 Aurinia Pharmaceuticals shares in Q3 2024, an estimated $457K.
Vontobel Holding first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 15 quarters.
Vontobel Holding's Aurinia Pharmaceuticals position peaked at $794K in Q2 2023.
183 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2024.

Based on Vontobel Holding's 13F filing for Q3 2024, filed 16 Oct 2024.